Navigation Links
VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Date:6/11/2009

-- the results of our clinical trials, including without limitation, with respect to the safety and efficacy of VIA-2291; -- if the results of the ACS and CEA studies, upon further review and analysis, are revised or negated by authorities or by later stage clinical trials; -- our ability to obtain necessary FDA approvals, including to initiate future clinical trials of VIA-2291; -- our ability to successfully commercialize VIA-2291; -- our ability to identify potential clinical candidates from the family of DGAT1 compounds licensed and move them into preclinical development; -- our ability to obtain and protect our intellectual property related to our product candidates; -- our potential for future growth and the development of our product pipeline, including the THR beta agonist candidate and the other compounds licensed from Roche; -- our ability to obtain strategic opportunities to partner and collaborate with large biotechnology or pharmaceutical companies to further develop VIA-2291; -- our ability to form and maintain collaborative relationships to develop and commercialize our product candidates; -- general economic and business conditions; and -- the other risks described under Item 1A "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008, as supplemented by the risks described under Item 1A "Risk Factors" in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2009, on file with the SEC.

All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above. Forward-looking statements speak only as of the date they are made, and VIA undertakes no obligation to update publicly any of these statements in light of n
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009
2. Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
3. ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
4. Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting
5. Arena Pharmaceuticals Announces Lorcaserin Data Demonstrating Highly Significant Categorical and Absolute Weight Loss and Improvements in Secondary Endpoints Associated with Cardiovascular Risk
6. Access Pharmaceuticals Announces Publication of Thiarabine Combination Data
7. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
8. Arena Pharmaceuticals Announces the Presentation of Lorcaserin Phase 3 BLOOM Data at the American Diabetes Associations 69th Scientific Sessions
9. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
10. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... (KOLs) can be the difference between a product,s success ... effectively map and stratify KOL targets – and then ... the type of strong relationships upon which successful KOL ... savvy pharma companies have identified internal inconsistencies in their ...
(Date:8/29/2014)... 29, 2014  A Boston Scientific Corporation (NYSE: ... stent removability and preliminary long term stricture resolution ... the August issue of the peer-reviewed journal, Gastroenterology. ... is being conducted in 11 countries and five ... metal stents (FCSEMS) after extended indwell (i.e., up ...
(Date:8/29/2014)... 29, 2014  BC Technical, the nation,s leading non-OEM ... Imaging, a leader in sales, service and installation of ... BC Technical to continue to expand their resources and ... CT modalities. "We are committed to ... Alvarez , president and CEO of BC Technical. "We ...
Breaking Medicine Technology:Implementing a Strategic Thought Leader Management & Engagement System 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4BC Technical Acquires Polaris Medical Imaging 2
(Date:9/1/2014)... HealthDay Reporter FRIDAY, Aug. 29, ... to two American aid workers successfully cured a group of ... report. The drug, ZMapp, prompted recovery in all 18 ... medication until five days after infection. ZMapp even cured ... even hours away from death, said study senior author Gary ...
(Date:9/1/2014)... Monday 1 September 2014: Permanent atrial fibrillation (AF) ... according to research in more than 6 000 patients ... from Belgium. The findings suggest that a simple clinical ... to better estimate stroke risk. , Ischaemic stroke is ... for over a million deaths and many more disabled ...
(Date:9/1/2014)... The National Association of Hispanic Nurses ( ... DNP, MPH, RN, and Adriana Perez, PhD, Rn, ANP-BC, ... Nursing. They will be inducted with Immediate Past President ... we reported last May. , Our three members will ... American Academy of Nursing Policy Conference in Washington, DC. ...
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 ... store, retrieve, organize and analyze biological and genetic ... of the activity of developing software tools to ... not to be confused with biological computation. While ... better understanding of biology can its related concepts, ...
(Date:9/1/2014)... Parties involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ... in September, where issues related to claims involving the ... of Pennsylvania, Bernstein Liebhard LLP reports. , According ... Court’s website, the meeting is scheduled to take place ... the latest of several Tylenol conferences that have taken ...
Breaking Medicine News(10 mins):Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 2Health News:Monkey Trial Supports Ebola Drug That May Have Helped 2 Stricken Americans 3Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 2Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 3Health News:Two Additional NAHN Members to be Inducted as Fellows of the American Academy of Nursing 4Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4
... you,re ready to drive again , , WEDNESDAY, Dec. 10 (HealthDay ... wheel again after orthopedic surgery or injury, but knowing when it,s ... , Orthopedic surgeons weigh in on the issue in the December ... , "Deciding when a patient can return to driving is ...
... (OTC Pink Sheets: SNDY ) is pleased to announce that ... by over 10% compared to the same time period for 2007. ... $28,509 for the same month last year. This marks the second ... of October. , , The Mammo ...
... Inc., a leading,provider of software and databases for systems ... Singapore Immunology Network (SIgN) has become a,certified GeneGo Center ... MetaCore, training and advanced support. SIgN COE will ... "We are excited ...
... Facilities , , NEW ... process, a proven commitment to clinical quality earned SigmaCare(R) ... Metropolitan Jewish Health System,s (Metropolitan) skilled nursing facilities. ... nationally recognized nonprofit organization, operates Metropolitan Jewish Geriatric Center, ...
... Pharma Services, Goodwill, , , ... NYSE: MDZ ), a leading provider of products and ... fiscal 2008 performance. , Based on preliminary information, MDS ... of $1,210 million to $1,220 million and adjusted EBITDA in the ...
... Care Insurance While They,re Still Healthy Enough to Qualify , ... If you,ve put off getting long term care insurance, ... new administration,s health plan? "I wouldn,t advise it," says Denise ... (LTCFP), one of the nation,s most experienced long term care ...
Cached Medicine News:Health News:Returning to the Road Tricky After Injury 2Health News:Solos Endoscopy, Inc. Increases Sales Revenue for October 2008 by Over 10% as Compared to Last Year 2Health News:A*STAR's Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 2Health News:Metropolitan Jewish Health System Awards Electronic Medical Records Contract to SigmaCare(R) 3Health News:MDS Provides Update on Fiscal 2008 Performance 2Health News:MDS Provides Update on Fiscal 2008 Performance 3Health News:MDS Provides Update on Fiscal 2008 Performance 4Health News:Obama Health Plan Not Likely to Embrace Long Term Care, Industry Leader Says 2
... OMNIPAQUE is an X-ray contrast ... and children for: angiography, urography, ... computed tomography of the basal ... endoscopic retrograde cholangio (pancreato) graphy ...
... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
... The only MR contrast agent FDA-approved ... is a gadolinium based, IV contrast media ... and liver. OptiMARK has convenient packaging ... contrast, packaged for efficient, problem-free delivery. You ...
... a contrast medium for Magnetic Resonance Imaging ... apyrogenic solution for intravenous injection. In MRI, ... brain, spine and surrounding tissues resulting in ... lesions with abnormal vascularity or those thought ...
Medicine Products: